Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach

American Journal of Gastroenterology

Volumn 98, Issue 2, 2003, Pages 495-499

  Hookman, Perry ^a   Barkin, Jamie S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOTRANSFERASE; GLUCOSE; LEPTIN; METFORMIN; PROTEIN; RNA; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BODY DISTRIBUTION; BODY FAT; CALORIC INTAKE; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FATTY LIVER; GLUCOSE BLOOD LEVEL; HEPATITIS; HEPATOMEGALY; HISTOPATHOLOGY; HYPERINSULINEMIA; INSULIN RESISTANCE; LIVER CELL; MALE; MOUSE; MOUSE STRAIN; NON ALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NOTE; OBESITY; OUTCOMES RESEARCH; PRIORITY JOURNAL;

EID: 0037282951     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)05998-1     Document Type: Note

References (42)

1. Ludwig J, Viggiano TR, et al. Nonalcoholic steatohepatitis. Mayo Clinic Proc 1980;55:434-38.
2. Falck-Ytter Y, Younossi ZM, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2002;21:17-26.
3. McCollough AJ, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology 1999;29:1328-30.
4. Propst A, Propst T, et al. Prognosis in nonalcoholic steatohepatitis. Gastroenterology 1995;108:1607 [letter].
5. Hultcrantz R, Glaumann H, et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986;21:109-13.
6. Hilden M, Christofferson P, et al. Liver histology in a normal population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-97.
7. Nonomura A, Mizukami Y, Unoura M, et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992;27:521.
8. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al. Idiopathic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103.
9. Moran JR, Ghishan FK, Halter SA, Graeme-Cook HL. Steatohepatitis in obese children: A cause of chronic liver dysfunction. Am J Gastroenterol 1983;78:374.
10. James O, Day C. Non-alcoholic steatohepatitis. Another disease of affluence. Lancet 1999;353:1634-6.
11. Galambos JT. Natural history of alcoholic hepatitis III. Histologic changes. Gastroenterology 1972;63:1026.
12. Marbet UA, Bianchi L, Meury U, Stadler GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol 1987;4:364.
13. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74.
14. Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol 1989;20:594.
15. Pinto HC, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172.
16. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413.
17. Galdwell SH, Oelsner DH, et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1998;29:664-9.
18. Marchesini G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-55.
19. Marceau P, et al. Liver pathology and metabolic syndrome x in severe obesity. Clin Endocrinol Metab 1999;84:1513-7.
20. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity of endotoxin liver injury: Implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;2557-62.
21. Uysai KT, Weisbrok SM, Marino MW, Motamislgil GS. Protection from obesity-induced insulin-resistance in mice lacking TNF-α function. Nature 1997;389:610-4.
22. Shimoura I, Basmokow Y, Horton JD. Increased nuclear levels of SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999;274:30028-8832.
23. Megalsson MD, et al. Antihyperglycemic actions of guanidenoakanoic acids; 3-guanidlnoproplonic acid and ameliorates hyperglycemia in diabetic KKAy and CS7BL-61/ob/ob mice and increases glucose disappearance in rhesus monkeys. J Pharmaol Exp Ther 1993;266:1454-62.
24. Campfield IA, Smith FI, Bum P. The OB protein (leptin) pathway - a link between adipose tissue mass and central neural networks. Horm Metab Res 1996;28:619-32.
25. Rouru I, Pesonen V, Kaulu M. Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. Life Sci 1992;50:1813-20.
26. Paolisso G, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998;28:441-6.
27. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
28. Day CP, Oliver FWJ. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998;114:842-5.
29. Ikejima K, Honda H, Yoshikawa M, et al. Leptin augments inflammatory and profibrogenic responses in the murine liverinduced by hepatotoxic chemicals. Hepatology 2001;34:288-97.
30. Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic profibrogenic and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-410.
31. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001;15:2565-71.
32. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002;282:G1-G5.
33. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998;244:178-82.
34. Marra F. Leptin and fatty liver fibrosis: A matter of fat. Gastroenterology 2002;122:1529-30.
35. Petersen KF, Oral EA, Dufour S, et al. Leptin reversed insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50.
36. Savage DB, O'Rahilly SO. Leptin: A novel therapeutic role in lipodystrophy. J Clin Invest 2002;109:1285-6.
37. Soloman SS, Mishra SK, Cwik C, et al. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res 1997;29:370-82.
38. Mc Clain CI, Hill DB, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liv Dis 1993;13:170-82.
39. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-52.
40. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
41. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
42. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.